Biotech: Page 47
-
PharmaVoice Team/PharmaVoice
What's New
New Healthcare-related Products, Services, and Companies Featured Briefs: TGaS Model Helps Solve Managed Markets Staffing Dilemma Razorfish Launches Independent, Dedicated Health Division FDA, NIH Collaborate to Speed Release of Medical Innovations Sidebar: On The Shelves PSKW Adds Loyalty Relat...
By PharmaVoice Team • April 28, 2010 -
PharmaVoice Team/PharmaVoice
UpFront
Market Report U.S. Prescription Sales Grow U.S. sales of ethical pharmaceuticals and insulins through retail and non-retail channels grew 5.1% in 2009, reaching $300.3 billion, compared with growth of 1.8% in 2008. While the 32 innovative products launched last year brought important new treatm...
By PharmaVoice Team • April 28, 2010 -
Explore the Trendline➔
Stock via Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Table of Contents
10 Molecule to Market The drug development process from lead generation to patent expiration is complex, fraught with risk, and extremely time and cost intensive. 16 Drug Discovery Pharmaceutical companies are using state-of-the-art technologies to understand the basis of disease as a way to brin...
By PharmaVoice Team • April 5, 2010 -
PharmaVoice Team/PharmaVoice
James Sapirstein: Steering a Winning Course
In a troubled economic environment the recipe for success in the biotech industry requires several key ingredients: take one part optimist, mix with some business innovation, cultural adaptability, and promising science in a significant therapeutic field, and allow time to brew. It’s this combina...
By PharmaVoice Team • March 23, 2010 -
PharmaVoice Team/PharmaVoice
UpFront
Honors and Awards Kendle, Quintiles Named to Training Top 125 Kendle and Quintiles have been named to Training magazine’s Training Top 125, an annual list of the 125 companies that are unsurpassed in harnessing human capital. The Training Top 125 rankings are based on a wide array of benchmarkin...
By PharmaVoice Team • March 22, 2010 -
PharmaVoice Team/PharmaVoice
Biomarkers Across Drug Development
Biomarkers have a multitude of applications, such as detecting disease early on, identifying potential drug targets, predicting patient response to medication, and accelerating clinical trials. The promise of biomarkers to shorten drug development time and decrease costs in the long term is likel...
By Denise Myshko • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
In our lifetime… There are few, if any, of us who can say we have been lucky enough to escape the ravaging effects of cancer — be it ourselves, a significant other, family member, or friend. For more years than I care to remember, “a cure for cancer" has been just around the corner. Recently, Pre...
By Taren Grom • Jan. 25, 2010 -
PharmaVoice Team/PharmaVoice
E-Media
NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES The Rosetta Luminator system, a clientserver bioinformatics system for storing and analyzing microarray data, has been launched by Rosetta Biosoftware and Agilent Technologies Inc. The geneexpression data analysis solution was deve...
By PharmaVoice Team • Jan. 13, 2010 -
PharmaVoice Team/PharmaVoice
What's on your mind: Opinions
R&D will tell I am not sure that the mega company strategy/structure will support the trend toward biopharmaceutical products (and fur ther into the future, gene therapies) that offer therapeutic solutions for more specific diseases. The trend toward blockbuster product launches will give way...
By PharmaVoice Team • Jan. 13, 2010 -
PharmaVoice Team/PharmaVoice
John T. Spitznagel — A New Horizon
PharmaVOICE EARLY ON IN HIS CAREER,JOHN SPITZNAGEL SET HIS SIGHTS ON ONE DAY RUNNING A HEALTHCARE COMPANY. IN MAY 2002, AS CHAIRMAN AND CEO OF ESP PHARMA, HIS VISION BECAMEAREALITYONCEAGAIN. Mr. Spitznagel already has proven that he has what it takes to drive a company to success, having engineer...
By Kim Ribbink • Jan. 11, 2010 -
PharmaVoice Team/PharmaVoice
Contents
In Every Issue 3 Letter from the Editor 8 Upfront A brief review of industry news at press time 36 Pharma Trax Sales, marketing, and R&D trends from industry analysts 40 What’s New New healthcare-related products, services, and companies 42 E-Media New electronic and Web-based applications, s...
By PharmaVoice Team • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
Partners in Public Health
The first influenza pandemic of the 21st century is under way. H1N1 influenza A has affected more than 207 countries and overseas territories worldwide, according the World Health Organization. As of the end of November 2009, 622,482 cases have been reported, including more than 7,820 deaths. In ...
By Denise Myshko • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
Executive Coaching
The goal of coaching is the goal of good management: and that is to make the most of an organization’s valuable resources — Harvard Business Review he International Coach Federation (ICF), one of the largest worldwide resources for professional coaches, defines coaching as partnering with clien...
By Taren Grom • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
Dr. Thomas Steitz: The Right Chemistry
Brilliance begets brilliance, and from early in his career, Thomas Steitz, Ph.D., has learned from and kept company with some of the most highly lauded scientific minds of the 20th and 21st centuries. Over the years, breakthrough discoveries regarding the ribosome have led to Dr. Steitz being oft...
By Kim Ribbink • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
Talent Pool
Biotechnology POOL Dr. Diane JORKASKY Aileron Therapeutics Appoints Medical Chief Aileron Therapeutics, a biotechnology company discovering and developing a novel class of therapeutics called stapled peptides, has appointed Diane Jorkasky, M.D., senior VP, head of development and chief medical of...
By PharmaVoice Team • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
What's New
Oncology Performance Edge, Health Strategies Group’s recently launched strategic research service, helps marketing and sales executives in the oncology field improve brand performance by understanding how best to invest their resources. “The oncology market is significantly different from others,...
By PharmaVoice Team • Dec. 28, 2009 -
PharmaVoice Team/PharmaVoice
The Year Ahead
Looking back to the varying changes and pressures the industry has endured, and ahead to how the industry will need to reinvent itself to continue to prosper, companies are adapting to longer-term marketplace trends and evolving patient needs. The industry is facing pressure from the economic, re...
By Denise Myshko and Robin Robinson • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
The Safety First Era
The classwide requirement for Risk Evaluation and Mitigation Strategies (REMS) for opioid products is likely to have a profound impact on the pharmaceutical industry and healthcare. While most REMS involve only a medication guide — which is likely to have little impact on the prescribing process ...
By PharmaVoice Team • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
RNAI Technology
Coming of Age: RNAi Technology As advances in genetics continue to improve our understanding of disease, RNAi will have the opportunity to create entirely new classes of medicines. Researchers say RNA-based therapeutic technology will have a tremendous impact on pharmaceutical research in the n...
By Denise Myshko • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
The Innovation Challenge
There has been a great deal of discussion related to the challenges hampering innovation to create differentiated medicines. Never before have research and cutting-edge science been more important to ensure a steady flow of innovation. Much has been made of the industry’s decline in R&D pro...
By PharmaVoice Team • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
The Executive Suite
Meeting challenges head-on David E. I. Pyott, CBE Chairman of the Board and CEO Allergan Inc. Allergan draws stability, strength, and value from its growth equation — a business model that balances diverse specialties with a focused approach and a leadership presence in markets around the globe. ...
By PharmaVoice Team • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Stanley BARSHAY Dr. Richard BOWLES Richard CLARK Willie DEESE Kenneth FRAZIER Dr. Peter KIM Raul KOHAN Merck Unveils Post-Merger Organizational Structure Merck has announced its new organizational structure following the completion of its merger with Schering-Plough. The new M...
By PharmaVoice Team • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
On the Calendar
November 16-17 Pharmaceutical Coverage & Reimbursement Conference Washington, D.C. Q1 Productions, q1productions.com November 16-17 The 3rd Pediatric Clinical Trials Grand Hyatt Washington, Washington, D.C. ExL Pharma, exlpharma.com November 17-18, 2009 13th Advanced Forum on Structuring, Neg...
By PharmaVoice Team • Nov. 9, 2009 -
PharmaVoice Team/PharmaVoice
Index
Julian Adams, Ph.D. President, Research and Development and Chief Scientific Officer, Infinity Pharmaceuticals Inc. Brent Ahrens. General Partner, Canaan Partners Kenneth C. Aldrich. CEO, Chairman, and Co-Founder, International Stem Cell Corp. Meryl Allison. Principal, Deloitte Consulting Karl...
By PharmaVoice Team • Nov. 9, 2009 -
PharmaVoice Team/PharmaVoice
What's New
inVentiv Health’s recently launched risk evaluation and mitigation strategy (REMS) offering provides pharmaceutical and biotechnology clients with a customizable suite of REMS-related services that can be delivered through a single, integrated program. In an effort to assure safe use of prescript...
By PharmaVoice Team • Nov. 9, 2009
Previous
